Analysis indicates everolimus-eluting stents can result in improvements for higher-risk patients
Published date : 14 December 2011
Article date : 14 December 2011
Pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) randomized trials has been published in the Journal of the American College of Cardiology.
The study suggests that patients with short lesions in large vessels have low rates of MACE at 2 years after treatment with either EES or PES. In higher-risk patients with long lesions and/or small vessels, EES results in significant improvements in both clinical safety and efficacy outcomes.
The full report can be found here
Have you had experience of the XIENCE V Everolimus Eluting Coronary Stent? We'd love to know what you think.
Add your review to our device page here
